198 related articles for article (PubMed ID: 18533284)
1. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.
Virella G; Carter RE; Saad A; Crosswell EG; Game BA; ; Lopes-Virella MF
Clin Immunol; 2008 Jun; 127(3):394-400. PubMed ID: 18533284
[TBL] [Abstract][Full Text] [Related]
2. Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy.
Atchley DH; Lopes-Virella MF; Zheng D; Kenny D; Virella G
Diabetologia; 2002 Nov; 45(11):1562-71. PubMed ID: 12436340
[TBL] [Abstract][Full Text] [Related]
3. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.
Lopes-Virella MF; Hunt KJ; Baker NL; Virella G;
J Diabetes Complications; 2016; 30(4):693-9. PubMed ID: 26861948
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
Lopes-Virella MF; Virella G; Orchard TJ; Koskinen S; Evans RW; Becker DJ; Forrest KY
Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827
[TBL] [Abstract][Full Text] [Related]
5. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.
Ravandi A; Boekholdt SM; Mallat Z; Talmud PJ; Kastelein JJ; Wareham NJ; Miller ER; Benessiano J; Tedgui A; Witztum JL; Khaw KT; Tsimikas S
J Lipid Res; 2011 Oct; 52(10):1829-36. PubMed ID: 21821825
[TBL] [Abstract][Full Text] [Related]
6. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls.
Mironova M; Virella G; Virella-Lowell I; Lopes-Virella MF
Clin Immunol Immunopathol; 1997 Oct; 85(1):73-82. PubMed ID: 9325072
[TBL] [Abstract][Full Text] [Related]
7. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events.
Tsimikas S; Brilakis ES; Lennon RJ; Miller ER; Witztum JL; McConnell JP; Kornman KS; Berger PB
J Lipid Res; 2007 Feb; 48(2):425-33. PubMed ID: 17093289
[TBL] [Abstract][Full Text] [Related]
8. Reduced IgM levels and elevated IgG levels against oxidized low-density lipoproteins in HIV-1 infection.
Yilmaz A; Jennbacken K; Fogelstrand L
BMC Infect Dis; 2014 Mar; 14():143. PubMed ID: 24636004
[TBL] [Abstract][Full Text] [Related]
9. Anti-cardiolipin antibodies and circulating immune complexes in type 1 diabetes mellitus: increased prevalence and relation to vascular complications.
Ahmed E; Nityanand S; Mustafa A; Brismar K; Lefvert AK
Clin Exp Immunol; 1999 Feb; 115(2):255-9. PubMed ID: 9933450
[TBL] [Abstract][Full Text] [Related]
10. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes.
Lopes-Virella MF; Carter RE; Baker NL; Lachin J; Virella G;
Nephrol Dial Transplant; 2012 Apr; 27(4):1416-23. PubMed ID: 21856760
[TBL] [Abstract][Full Text] [Related]
11. Natural antibodies to oxidation-specific epitopes: innate immune response and venous thromboembolic disease.
Eichinger S; Kyrle PA; Kammer M; Eischer L; Ozsvar Kozma M; Binder CJ
J Thromb Haemost; 2018 Jan; 16(1):31-35. PubMed ID: 29045005
[TBL] [Abstract][Full Text] [Related]
12. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
[TBL] [Abstract][Full Text] [Related]
13. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL.
Virella G; Atchley D; Koskinen S; Zheng D; Lopes-Virella MF;
Clin Immunol; 2002 Oct; 105(1):81-92. PubMed ID: 12483997
[TBL] [Abstract][Full Text] [Related]
14. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement.
Lopez LR; Simpson DF; Hurley BL; Matsuura E
Ann N Y Acad Sci; 2005 Jun; 1051():313-22. PubMed ID: 16126973
[TBL] [Abstract][Full Text] [Related]
15. Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis.
Lopez LR; Salazar-Paramo M; Palafox-Sanchez C; Hurley BL; Matsuura E; Garcia-De La Torre I
Lupus; 2006; 15(2):80-6. PubMed ID: 16539278
[TBL] [Abstract][Full Text] [Related]
16. Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE and APOECD40L mice.
Smook ML; van Leeuwen M; Heeringa P; Damoiseaux JG; Theunissen R; Daemen MJ; Lutgens E; Tervaert JW
Clin Exp Immunol; 2008 Nov; 154(2):264-9. PubMed ID: 18778362
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis.
Lopes-Virella MF; Virella G
J Atheroscler Thromb; 2013; 20(10):743-54. PubMed ID: 23965492
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies against oxidized low-density lipoprotein and lipid profile in patients with chronic periaortitis: case-control study.
van Bommel EF; van Tits LJ; van den Berg EA; Prins J; Stalenhoef AF
Rheumatol Int; 2011 Feb; 31(2):201-8. PubMed ID: 20012624
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of the humoral immune response to modified LDL.
Lopes-Virella MF; Virella G
Clin Immunol; 2010 Jan; 134(1):55-65. PubMed ID: 19427818
[TBL] [Abstract][Full Text] [Related]
20. Detection of IgG-bound lipoprotein(a) immune complexes in patients with coronary heart disease.
Wang J; Qiang H; Zhang C; Liu X; Chen D; Wang S
Clin Chim Acta; 2003 Jan; 327(1-2):115-22. PubMed ID: 12482626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
